Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Amicus Therapeutics
(NASDAQ:FOLD)
Intraday
$10.29
-0.04
[-0.39%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$10.29
-0.04
[-0.39%]
Last update: 9:30AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Amicus Therapeutics Stock (NASDAQ:FOLD)
Amicus Therapeutics Stock (NASDAQ: FOLD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 18, 2024
JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $19
Benzinga Newsdesk
-
Mar 18, 2024, 7:49AM
Thursday, February 29, 2024
Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $22 Price Target
Benzinga Newsdesk
-
Feb 29, 2024, 1:47PM
Wednesday, February 28, 2024
Amicus Therapeutics Projects 2024 Galafold Revenue Growth Of 11-16% At CER, Anticipates Full-Year Non-GAAP Profitability In 2024
Benzinga Newsdesk
-
Feb 28, 2024, 7:07AM
Amicus Therapeutics Q4 Adj EPS $0.01 Beats $(0.06) Estimate, Sales $115.08M Beat $114.33M Estimate
Benzinga Newsdesk
-
Feb 28, 2024, 7:06AM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Thursday, February 08, 2024
Amicus Therapeutics Says It Received 2024 New Treatment Award For Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) At 20th Annual WORLDSymposium
Benzinga Newsdesk
-
Feb 8, 2024, 7:14AM
Sunday, January 07, 2024
Amicus Therapeutics Reports Preliminary 2023 Revenue And Provides 2024 Strategic Outlook; Q4 Revenue ~$115.1M Vs $112.25M Est.; Sees FY23 Revenue Of ~$399.4M Vs $396.45M Est.; Co Sees FY24 As First Full Year Of Achieving Non-GAAP Profitability
Benzinga Newsdesk
-
Jan 7, 2024, 5:38PM
Tuesday, December 19, 2023
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Benzinga Insights
-
Dec 19, 2023, 10:01AM
Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20
Benzinga Newsdesk
-
Dec 19, 2023, 9:09AM
Tuesday, December 05, 2023
Amicus Therapeutics' John Crowley, Executive Chairman, Will Step Down, Effective March 4, 2024, Michael Raab, Lead Independent Director, Will Become The Chairman
Benzinga Newsdesk
-
Dec 5, 2023, 6:05AM
Thursday, November 09, 2023
Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Raises Price Target to $15
Benzinga Newsdesk
-
Nov 9, 2023, 8:54AM
Wednesday, November 08, 2023
Amicus Therapeutics Is On-Track To Achieve Non-GAAP Profitability In Q4 2023
Benzinga Newsdesk
-
Nov 8, 2023, 7:13AM
For FY23, Amicus Therapeutics Is Increasing Galafold Revenue Growth Guidance To Between 16 And 18% At CER
Benzinga Newsdesk
-
Nov 8, 2023, 7:11AM
Amicus Therapeutics Q3 EPS $(0.07) Beats $(0.08) Estimate, Sales $103.50M Beat $101.36M Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 7:10AM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Tuesday, October 10, 2023
Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14
Benzinga Newsdesk
-
Oct 10, 2023, 11:17AM
Monday, October 02, 2023
Amicus Therapeutics And Blackstone Enter Into $430M Strategic Financing Collaboration; Blackstone To Also Purchase $30M Of Amicus Common Stock
Benzinga Newsdesk
-
Oct 2, 2023, 8:22AM
Friday, September 29, 2023
JP Morgan Maintains Overweight on Amicus Therapeutics, Raises Price Target to $19
Benzinga Newsdesk
-
Sep 29, 2023, 7:25AM
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Lisa Levin
-
Sep 29, 2023, 5:59AM
Thursday, September 28, 2023
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
Vandana Singh
-
Sep 28, 2023, 12:41PM
Amicus Therapeutics Shares Resume Trade
Benzinga Newsdesk
-
Sep 28, 2023, 11:10AM
Amicus Therapeutics, Inc. Shares To Resume Trade At 11:10 a.m. ET
Benzinga Newsdesk
-
Sep 28, 2023, 10:52AM
Amicus Therapeutics Announces FDA Approval And Launch Of New Treatment For Pompe Disease
Benzinga Newsdesk
-
Sep 28, 2023, 10:43AM
Amicus Therapeutics Shares Halted, News Pending
Benzinga Newsdesk
-
Sep 28, 2023, 8:29AM
Monday, August 21, 2023
Amicus Therapeutics Appoints Simon Harford As Chief Financial Officer Effective Immediately; Daphne Quimi To Retire At Year End
Benzinga Newsdesk
-
Aug 21, 2023, 7:18AM
Tuesday, August 15, 2023
Amicus Therapeutics Announces Approval And Launch Of New Pompe Disease Therapy In The United Kingdom
Benzinga Newsdesk
-
Aug 15, 2023, 7:02AM
Tuesday, August 08, 2023
Amicus Therapeutics shares are trading higher following a Q2 revenue beat.
Bill Haddad
-
Aug 8, 2023, 1:05PM
Amicus Therapeutics Q2 EPS $(0.15) Misses $(0.12) Estimate, Sales $94.50M Beat $89.87M Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 7:05AM
Earnings Scheduled For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 4:48AM
Tuesday, July 11, 2023
Morgan Stanley Reiterates Equal-Weight on Amicus Therapeutics, Maintains $15 Price Target
Benzinga Newsdesk
-
Jul 11, 2023, 8:57AM
Monday, June 26, 2023
Amicus Therapeutics Gets European Commission Approval Of Opfolda For The Treatment Of Adults Living With Late-Onset Pompe Disease.
Happy Mohamed
-
Jun 26, 2023, 10:29AM
Wednesday, May 10, 2023
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
Vandana Singh
-
May 10, 2023, 2:16PM
Earnings Scheduled For May 10, 2023
Benzinga Insights
-
May 10, 2023, 9:12AM
Amicus Therapeutics Expects FY23 Galafold Revenue Growth Of 12%-17% at CER; On-Track For Adj Profitability In 2H of 2023
Benzinga Newsdesk
-
May 10, 2023, 7:25AM
Amicus Therapeutics: Q1 Earnings Insights
Benzinga Insights
-
May 10, 2023, 7:15AM
Amicus Therapeutics Q1 EPS $(0.18) Misses $(0.15) Estimate, Sales $86.27M Beat $83.08M Estimate
Benzinga Newsdesk
-
May 10, 2023, 7:01AM
Wednesday, April 26, 2023
Amicus Therapeutics Receives Positive Committee For Medicinal Products For Human Use Opinion For Opfolda For Late-Onset Pompe Disease
Happy Mohamed
-
Apr 26, 2023, 1:03PM
Monday, April 24, 2023
Amicus Therapeutics On Apr. 18 Entered Supply And Manufacturing Services Agreement With Wuxi; Wuxi To Manufacture, Supply To Amicus, Amicus To Purchase From Wuxi, API In ATB200 And Finished Enzyme Replacement Drug Product
Benzinga Newsdesk
-
Apr 24, 2023, 8:52AM
Tuesday, April 11, 2023
Amicus Therapeutics Granted Two U.S. Patents Tuesday: Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same; Methods Of Treating Fabry Patients Having Renal Impairment
Charles Gross
-
Apr 11, 2023, 9:39AM
Tuesday, March 28, 2023
The Latest Analyst Ratings for Amicus Therapeutics
Benzinga Insights
-
Mar 28, 2023, 11:02AM
B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17
Benzinga Newsdesk
-
Mar 28, 2023, 10:23AM
Monday, March 27, 2023
Amicus Therapeutics Secures European Commission Approval For Pombiliti In Patients With Late-Onset Pompe Disease
Benzinga Newsdesk
-
Mar 27, 2023, 7:09AM
Monday, March 20, 2023
Amicus Therapeutics Gets European Commission Approval Of Pombiliti For The Treatment Of Late-Onset Pompe Disease
Happy Mohamed
-
Mar 20, 2023, 12:54PM
Thursday, March 02, 2023
UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $17
Benzinga Newsdesk
-
Mar 2, 2023, 9:33AM
Goldman Sachs Maintains Neutral on Amicus Therapeutics, Raises Price Target to $11
Benzinga Newsdesk
-
Mar 2, 2023, 9:06AM
Wednesday, March 01, 2023
Amicus Therapeutics Q4 Sales $88.10M Beat $86.29M Estimate
Benzinga Newsdesk
-
Mar 1, 2023, 7:11AM
Earnings Scheduled For March 1, 2023
Benzinga Insights
-
Mar 1, 2023, 6:59AM
Tuesday, February 28, 2023
Earnings Preview: Amicus Therapeutics
Benzinga Insights
-
Feb 28, 2023, 2:01PM
Wednesday, January 25, 2023
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
Lisa Levin
-
Jan 25, 2023, 8:53AM
Wednesday, January 18, 2023
BTIG Maintains Buy on Amicus Therapeutics, Raises Price Target to $16
Benzinga Newsdesk
-
Jan 18, 2023, 8:38AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch